Applying Value-Based Principles in ATTR-CM Care: Optimizing Identification, Therapy Selection, and Patient Access

This activity was originally presented live at Asembia's AXS26 Summit in Las Vegas, Nevada

Program Description

Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is an underrecognized, progressive, and fatal condition characterized by the systemic deposition of misfolded transthyretin protein in the myocardium. For years, treatment options were limited to supportive care, leaving patients to face a heavy burden of cardiovascular morbidity and a steady decline in functional independence. Modern management, however, has transitioned toward disease-modifying therapies, yet significant challenges remain regarding high therapy costs, complex specialty pharmacy workflows, and the clinical difficulty of early recognition of ATTR-CM. The therapeutic landscape is now expanding further with emerging gene-silencing strategies, which offer the advantage of potent TTR reduction and subcutaneous dosing. These advancements necessitate that specialty and managed care pharmacists are equipped to navigate evolving evidence on treatment sequencing, combination strategies, and the interpretation of biomarkers like serum TTR. This session features an expert-led discussion of the latest clinical guidelines and real-world evidence to support individualized treatment planning for patients with ATTR-CM. Faculty experts will examine the critical role of specialty and managed care pharmacists in orchestrating multidisciplinary care, from streamlining diagnostic pathways and managing complex distribution processes to implementing evidence-based protocols that ensure long-term adherence and improved quality of life for patients with ATTR-CM.

Target audience: Managed Care Pharmacist, Specialty Pharmacist
Type of activity: Application
Release date: May 11, 2026
Expiration date: May 11, 2027
Learner level: Foundational, Intermediate
Time to complete activity: 1.5 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explain the burden of transthyretin amyloidosis cardiomyopathy (ATTR-CM), including misdiagnosis, quality-of-life impact, and drivers of health care utilization
• Interpret current treatment recommendations for ATTR-CM, incorporating mechanisms of action, dosing, administration, and safety considerations for approved and emerging therapies
• Apply available clinical evidence for approved and investigational ATTR-CM therapies to support individualized treatment planning
• Exercise strategies to reduce care burden and improve access, leveraging multidisciplinary coordination to optimize therapy initiation and ongoing management in ATTR-CM

Accreditation

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-26-107-H01-P. The activity is available for CE credit through May 11, 2027.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Dejan Landup, PharmD, HF-Cert, has the following relevant financial relationships with ineligible companies to disclose: Regional advisory board: Alnylam, BridgeBio.

Victoria Wolf, PharmD, has no relevant financial relationships with ineligible companies to disclose.

Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Rose Buszka, PharmD, BCPS, CHCP; Katie Naspo; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships with ineligible companies to disclose.

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com

Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms